Theseus Reports Initial Dose Escalation Data From Ongoing Phase 1/2 Trial Of THE-630 In Patients With Advanced GIST
Portfolio Pulse from Benzinga Newsdesk
Theseus Pharmaceuticals reports initial dose escalation data from its ongoing Phase 1/2 trial of THE-630 in patients with advanced GIST, showing an encouraging safety profile and evidence of clinical activity in heavily pre-treated patients.
May 25, 2023 | 9:09 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Theseus Pharmaceuticals' ongoing Phase 1/2 trial of THE-630 in advanced GIST patients demonstrates an encouraging safety profile and clinical activity, potentially benefiting the company's stock.
The positive initial results from the Phase 1/2 trial of THE-630 in advanced GIST patients indicate that the drug has an encouraging safety profile and clinical activity. This news is likely to be well-received by investors, potentially leading to an increase in Theseus Pharmaceuticals' stock value in the short term.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100